HMGCR: a malignancy hub - frontiers in cancer diagnosis and therapy
Open Access
- 10 December 2025
- journal article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15
Abstract
Cholesterol metabolism is significantly activated during most tumor growth. As a key rate-limiting enzyme in cholesterol synthesis, HMG-CoA reductase (HMGCR) affects tumor metabolic reprogramming by upregulating cholesterol metabolism and promotes tumor growth and immune escape by remodeling the tumor microenvironment. It fuels tumor growth by providing cholesterol and isoprenoids, regulating critical pathways (Hippo, Hedgehog, MAPK), and modulating ferroptosis sensitivity. A complex bidirectional relationship exists between HMGCR and the pro-inflammatory cytokine TNF-α: TNF-α can inhibit HMGCR activity and thus inhibit cholesterol synthesis. At the same time, HMGCR influences TNF-αmediated inflammation and immune evasion. Statins, as HMGCR inhibitors, have shown anti-tumor effects in experiments. However, clinical application faces challenges including highly toxic concentration, drug resistance and tissue specificity. Accordingly, further exploration of mechanism-based targeted precision therapies to intervene in the HMGCR-TNF-α axis and related pathways, as well as the development of novel HMGCR inhibitors or optimization of existing drugs, represents an innovative strategy to enhance cancer treatment efficacy and advance drug development.Keywords
This publication has 93 references indexed in Scilit:
- The Role of Cholesterol Metabolism and Its Regulation in Tumor DevelopmentCancer Medicine, 2025
- 25-Hydroxycholesterol attenuates tumor necrosis factor alpha-induced blood-brain barrier breakdown in vitroBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- The mevalonate pathway contributes to breast primary tumorigenesis and lung metastasisMolecular Oncology, 2024
- BRCC36 Deubiquitinates HMGCR to Regulate the Interplay Between Ferroptosis and PyroptosisAdvanced Science, 2024
- 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR) protects hair cells from cisplatin‐induced ototoxicity in vitro: possible relation to the activities of p38 MAPK signaling pathwayArchives of Toxicology, 2023
- The fat side of prostate cancerBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2013
- Regulation of HMG‐CoA reductase expression by hypoxiaJournal of Cellular Biochemistry, 2008
- Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patientsBiochemical and Biophysical Research Communications, 2007
- P38 MAPK protects against TNF-α-provoked apoptosis in LNCaP prostatic cancer cellsApoptosis, 2006
- RhoA and p38 MAPK mediate apoptosis induced by cellular cholesterol depletionApoptosis, 2006